TNFRSF1A rs1800626: Understanding This Genetic Variant
The rs1800626 variant is a single nucleotide polymorphism located in the promoter region of the TNFRSF1A gene. It is associated with differences in how the body sheds TNF receptors, which may influence individual susceptibility to certain auto-inflammatory responses.
What each genotype means
Typical receptor shedding profile
This genotype represents the most common form of the TNFRSF1A promoter region. Research suggests this version is associated with standard rates of receptor shedding, which is a process that helps regulate inflammatory responses. As this is the common variant, it is generally considered the baseline for comparison in studies of auto-inflammatory susceptibility.
Carried by the majority of individuals in most global populations, though frequencies vary by ancestry.
Intermediate receptor shedding profile
Individuals with this genotype carry one copy of the minor allele, which has been studied for its potential influence on TNFR1 receptor shedding and inflammatory signaling. While associations with auto-inflammatory traits have been explored, the evidence remains limited and inconsistent across different populations. You should discuss any specific health concerns with a qualified clinician.
Carried by roughly 1 in 3 to 1 in 4 people of European ancestry; it is less common in East Asian populations.
Altered receptor shedding profile
This genotype involves two copies of the minor allele, which has been associated in some research with differential receptor shedding and potentially altered susceptibility to auto-inflammatory responses. Because the evidence linking this specific variant to clinical outcomes is limited, it is not used to predict individual disease risk. Please consult with a healthcare provider if you have questions about your inflammatory health.
Carried by approximately 3-4% of individuals of European ancestry; it is rare in many other global populations.
What is rs1800626?
The rs1800626 variant is a specific change in the DNA sequence located within the promoter region of the TNFRSF1A gene. A promoter region acts as an on-off switch for a gene, determining how much protein is produced. Because this variant sits in a regulatory area rather than the protein-coding sequence itself, it does not change the structure of the resulting protein. Instead, it is thought to influence the efficiency or frequency with which the gene is expressed. In genetic research, this is classified as a single nucleotide polymorphism, or SNP, representing a common variation where one building block of DNA is swapped for another. Scientists study these promoter variants to understand how subtle differences in gene regulation can contribute to biological diversity and, in some cases, variations in how our immune systems respond to environmental triggers.
The Role of the TNFRSF1A Gene
The TNFRSF1A gene provides the instructions for creating the tumor necrosis factor receptor 1 (TNFR1) protein. This protein is embedded in the membranes of many cell types throughout the body, particularly within the hematopoietic system, which includes blood-forming cells. TNFR1 acts as a receptor for tumor necrosis factor (TNF), a signaling molecule that plays a critical role in inflammation and immune system regulation. When TNF binds to the receptor, it can trigger a cascade of signals that lead to inflammation or, in some contexts, programmed cell death. A key feature of this system is 'receptor shedding,' where the receptor is cleaved from the cell surface and released into the bloodstream. This soluble form of the receptor can bind to free TNF, effectively acting as a sponge to inhibit or dampen inflammatory signals. Proper regulation of this process is essential for maintaining immune balance.
Research and Evidence Strength
Research into rs1800626 has primarily focused on its association with the regulation of TNFR1 shedding and its potential link to auto-inflammatory conditions. While some studies suggest that this variant may influence the levels of soluble TNFR1 in the blood, the clinical significance of these findings remains limited. It is important to distinguish this common promoter variant from the rare, highly penetrant mutations in TNFRSF1A that are known to cause TNF receptor-associated periodic syndrome (TRAPS). Unlike those rare mutations, which have a clear and direct impact on protein function and disease, the evidence linking rs1800626 to specific health outcomes is mixed and often requires further validation. Current scientific consensus suggests that while this variant may play a role in modulating immune responses, it is not a definitive predictor of disease on its own, and its effects are likely influenced by a complex interplay of other genetic and environmental factors.
What This Information Means for You
If you have received information about your status for rs1800626, it is important to view it within the context of current scientific understanding. This variant is a common genetic feature, and its presence does not constitute a medical diagnosis. Because the evidence linking this SNP to specific health conditions is limited and often inconsistent across different studies, it cannot be used to predict your personal risk for inflammatory diseases. Genetic information is only one piece of a much larger puzzle that includes your overall health history, lifestyle, and other genetic factors. If you have concerns about your immune health or symptoms of inflammation, the most appropriate step is to consult with a qualified healthcare professional. They can provide a comprehensive evaluation based on clinical evidence rather than relying on a single genetic marker. Never make changes to your health management or medication based on genetic test results without professional guidance.
How common is this variant?
The minor allele frequency for rs1800626 is approximately 0.15 to 0.20 in European cohorts, making it a relatively common variant in these populations.
Frequently asked questions
Is rs1800626 a cause of TRAPS?
No, rs1800626 is a common promoter variant and is not considered a cause of TNF receptor-associated periodic syndrome (TRAPS). TRAPS is typically caused by rare, pathogenic mutations in the coding region of the TNFRSF1A gene.
Can I use this result to predict my risk of autoimmune disease?
No, this variant is not a diagnostic tool. The evidence linking it to disease risk is limited and insufficient for clinical prediction.
What should I do if I have the minor allele?
No specific action is required. This variant is common in the general population and is not a marker for a specific medical condition.
Does this variant affect how I respond to medication?
There is no established clinical evidence that this variant dictates medication response. Always discuss any concerns about your medications with your doctor or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/16/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1800626?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29